



biomotion

Automation & Reliability
in 3D Bioprinting

3D Bioprinting Systems for the Reproducible
Biofabrication of Human Tissues



3D Bioprinting of human tissues suffers from a high process variability: up to 20% Weight Variation in Produced Tissue Constructs



High Material & Time Waste

Inconsistency
wastes valuable donor material
that took months to grow



Challenging Regulatory Approval

Lack of reproducibility
hinders regulatory approval
for clinical use


Source: Customer research, interviews with tissue engineering and pharmaceutical companies, literature research

¹ QMS: quality management system needed to reach a GMP (good manufacturing practice) lock for eventual clinical use



3D Bioprinting System incl. quality assurance

guarantees reproducible fabrication & minimize tissue rejects



First Bioprinting System with in-line, sterile and non-destructive quality assurance system

Sensor-software solution tracks accuracy of fabricated tissue product and adjusts printing parameters in real-time, if needed.

Process data used as quality criteria for regulatory approval of construct and for company's in-house QMS



Our Team



Dr. Gregor Weisgrab, M.Sc.
CEO, Finances and Customer Acquisition

PhD in automation for tissue engineering applications (TU Wien),
2 master degrees in Biofabrication



Dr. Diego Castaneda, M.D., M.Sc.
CTO, Head of Product and After Sales

General surgeon with an engineering background
2 master degrees on Biofabrication



Elder Linssen, M.Sc.
Go-To-Market Strategy, Marketing and Sales

Product Marketing Manager at Ultimaker (Industrial 3D Printing),
M.Sc “Tissue Engineering and Regenerative Medicine”




Traction




**Partnership for
technology validation**

1-year validation with
2 academic partners



**First Sales of
3D Bioprinting-Systems**

> 60k € income with
first 2 systems sold







**3 Letter of Intents for
Process supervision system**

3 biopharmaceutical companies
interested in implementing our
systems in their production line



Business Model




-  One-time revenue
-  Recurring revenue



Addressable Markets


- 3D Bioprinting market worldwide estimated at USD 11.8 B, with CAGR of 18.8%
- Market focus: biopharmaceutical companies that bring 3D bioprinted product to the market in Europe.
- Revenue potential: 40 devices sold in 4 years







Source: [MarketWatch.com](https://www.marketwatch.com)



Upcoming Roadmap



-  Funding
-  Open Development Platform for 3D Bioprinting
-  Production-grade system with process supervision



biomotion

Automation & Reliability in
3D Bioprinting

3D Bioprinting Systems for the Reproducible
Biofabrication of Human Tissues

Contact:

Dr. Gregor Weisgrab

gregor.weisgrab@biomotion.tech

+43 664 391 390 7



INNOVATION
INCUBATION
CENTER

austria
wirtschafts
service



I.E.C.T
HERMANN HAUSER

